Men and women ≥18 and ≤75 years old on the day of signing the ICF
At least 1 measurable lesion per RECIST v1.1
Expected survival ≥3 months
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1
Adequate organ function
Female participants of childbearing potential or male participants whose partner is a female of childbearing potential agree to use medically effective contraceptive methods from the date of signing the ICF until at least 6 months after the last dose of the IP, and during this period, male participants are not allowed to donate sperms
You may not be if
Active or pre-existing autoimmune diseases that may relapse
Pleural effusion, pericardial effusion, or intraperitoneal effusion accompanied with clinical symptoms, clinically poorly controlled, or requiring repeated drainage
Allergies to any component of ALK201 or other monoclonal antibodies
Primary central nervous system malignancies, or active metastases to central nervous system and/or metastases to meninges
Combined with ≥ Grade 2 stomatitis and/or nose bleeding at screening
Vaccinated with live vaccines within 4 weeks prior to the first dose
Clareo Health | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
